Cough And Cold Preparation Patents (Class 514/849)

Cross-Reference Art Collections

Antitussive (Class 514/850)
  • Patent number: 10150731
    Abstract: The present invention describes a novel method for preparing 4-cyanopiperidine hydrochloride.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: December 11, 2018
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Thomas Himmler, Dirk Brohm
  • Patent number: 8703158
    Abstract: The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: April 22, 2014
    Assignee: Biocopea Limited
    Inventors: John Brew, Robin Mark Bannister
  • Patent number: 8501816
    Abstract: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: August 6, 2013
    Assignee: Cerecor, Inc.
    Inventors: Blake Paterson, Mark Ginski, Brendan Canning
  • Patent number: 8349897
    Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: January 8, 2013
    Assignee: Astrazeneca AB
    Inventors: Timothy Jon Luker, Rukhsana Tanseem Mohammed, Mark Dickinson, Stephen Thom
  • Patent number: 8293796
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: October 23, 2012
    Assignee: University College London
    Inventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
  • Patent number: 8257746
    Abstract: Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: September 4, 2012
    Assignee: Pernix Therapeutics, LLC
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Patent number: 8012506
    Abstract: Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: September 6, 2011
    Assignee: Pernix Therapeutics, LLC
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Patent number: 7989003
    Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: August 2, 2011
    Assignee: Zicam, LLC
    Inventors: Charles Hensley, Robert Steven Davidson
  • Patent number: 7887846
    Abstract: A process for producing microspheres was developed that provides microspheres that are swellable and degradable. The process is reliable and high yielding, and makes use of a low temperature azo initiator, a small molecule chlorinated solvent as the organic phase, and a heat treatment step, and is carried out in absence of a crosslinking agent. The microsphere preparation made using the process is particularly useful as a degradable embolic material.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: February 15, 2011
    Assignee: E. I. du Pont de Nemours and Company
    Inventor: Garret D. Figuly
  • Patent number: 7867523
    Abstract: A pharmaceutical composition for the treatment of colds and influenza. The pharmaceutical composition is a mixture of: acetaminophen, diphenhydramine, dextromethorphan, arabinogalactan, vitamin C, zinc, olive leaf extract, resveratrol and elderberry extract.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: January 11, 2011
    Inventor: Elaine A. Vanterpool
  • Patent number: 7135195
    Abstract: We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5–40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: November 14, 2006
    Assignee: American Silver, LLC
    Inventors: Robert J. Holladay, Herbert Christensen, William D. Moeller
  • Patent number: 7094429
    Abstract: An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: August 22, 2006
    Assignee: Kiel Laboratories, Inc.
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Patent number: 7087249
    Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: August 8, 2006
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
  • Patent number: 7060730
    Abstract: The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: June 13, 2006
    Inventors: Cathy Klech Gelotte, Joanna F. Hills, Charles E. Pendley, II, Manoj N. Shah
  • Patent number: 6989157
    Abstract: Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: January 24, 2006
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Scott H. Gillis, Paul Schechter, Robert E. Burrell
  • Patent number: 6939550
    Abstract: An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: September 6, 2005
    Assignee: Schering Corporation
    Inventors: Farah J. Munayyer, Frank Guazzo, Elliot I. Stupak, Imtiaz A. Chaudry, Joel A. Sequeira
  • Patent number: 6932966
    Abstract: A skin treatment mixture for treating pierced skin such as that resulting from a body piercing procedure includes sea salt, lysozyme and reconstituted ocean water. The reconstituted ocean water preferably is the product of reverse osmosis of water. The skin treatment mixture preferably additionally includes sodium benzoate to act as a preservative. A method of producing a skin treatment mixture includes the steps of providing a quantity of purified water; adding a quantity of sea salt to the quantity of purified water; boiling the purified water and sea salt; cooling the purified water and sea salt; adding a quantity of lysozyme to the purified water and sea salt; sterilizing the mixture and testing it for bacteria. A method of treating a pierced skin area includes the step of applying to the pierced area a reconstituted ocean water mixture of sea salt and lysozyme.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: August 23, 2005
    Inventor: Edward Kolos
  • Patent number: 6932978
    Abstract: A double-headed, closed-mouth cough suppressant and cold relief device in which an individual having the symptoms of a cough is able to suppress the cough by inserting the device into an open mouth, and by sucking on one end of the device, is able to release a menthol medicament disposed within the device to thereby suppress a cough. Additionally, by sucking on another end of the device a eucalyptus medicament is released to thereby relieve a sore throat. By suppressing the cough, the device prevents the spread of germs to the immediate environment.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: August 23, 2005
    Inventor: James Benjamin Huntley
  • Patent number: 6929800
    Abstract: A nasal passage cleaning composition according to the invention comprises water and salt as a base, and contains a mucolytic agent such as alum and/or zinc sulphate to shrink the mucosa and allow sinus passage drainage, decreasing pressure in the infected sinus an alleviates sinus headache and face ache. A preferred mucolytic agent is n-acetyl-L-cystine, which is used to dissolve or soften mucus in the nasal passages, though methyl salicylate may also be used to disintegrate crusted mucus, acting also as a topical anti-inflammatory agent and as a pain relieving agent to reduce pain and discomfort.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: August 16, 2005
    Inventor: Abdul Rasoul Salman
  • Patent number: 6869618
    Abstract: An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: March 22, 2005
    Assignee: Kiel Laboratories, Inc.
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Patent number: 6866871
    Abstract: Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: March 15, 2005
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Scott H. Gillis, Paul Schechter, Robert E. Burrell
  • Patent number: 6790849
    Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: September 14, 2004
    Assignee: Sepracor Inc.
    Inventor: Paul D. Rubin
  • Patent number: 6767901
    Abstract: The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high ciclesonide retentivity and permeability to the submucosa or the blood at the mucosa.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: July 27, 2004
    Assignee: Altana Pharma AG
    Inventors: Atsuhiro Nagano, Yoshihisa Nishibe, Kazuya Takanashi
  • Patent number: 6703376
    Abstract: A method of promoting drainage of mucous secretions in the congested airways of a bedridden/immobilized patient or an intubated/mechanically-ventilated patient is disclosed. The method comprises administering to the airways of the patient a uridine phosphate such as uridine 5′-triphsophate(UTP) or P1,P4-di(uridine-5′) tetraphosphate, an analog of UTP, or any other analog, in an amount effective to promote drainage of fluid in the congested airways, including sinuses, to create the ciliary beat frequency of cilia on the surface lumina epithelia cells, to increase the secretions of mucous by goblet cells and to promote the clearance of retained secretions by hydrating mucous secretions, by stimulating ciliary beat frequency in the airways and by stimulating surfactant production. Pharmaceutical formulations and methods of making the same are also disclosed.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: March 9, 2004
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: Karla M. Jacobus, H. Jeff Leighton
  • Patent number: 6696041
    Abstract: The invention relates generally to a method which utilizes iodine as a broad spectrum microbicide wherein the active agent may be applied in nasal passages in the manner of a decongestant type nose spray. The spray is intended particularly for human use. It is to be applied in the event of known or suspected exposure of the individual to common cold virus, flu, or other infective microbial agents including for example, bacteria, viruses, rickettsia, and even mold and fungus. The active agent is based on an iodine solution and may also contain one or more of the following: sodium hypochlorite solution, or a solution of chlorine or hypochlorites plus a salt of chloride, bromide or iodide. Alternatively, the solution may further contain iodine and a bromine solution, or a solution of iodine, bromine plus a salt of chloride, bromide or iodide such as sodium chloride, zinc chloride, sodium bromide, zinc bromide, sodium iodide or zinc iodide.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: February 24, 2004
    Inventor: Richard L. Hansen
  • Patent number: 6677381
    Abstract: The invention pertains to a novel composition comprising guaifenesin tannate and to a method for preparing guaifenesin tannate by reacting guaifenesin with tannic acid at a temperature above the melting point of guaifenesin. The guaifenesin tannate has extended release properties and is useful in pharmaceutical compositions as an expectorant in warm-blooded animals or as a muscle relaxant in non-human animals.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: January 13, 2004
    Assignee: Jame Fine Chemicals, Inc.
    Inventors: James R. Schleck, Vilas M. Chopdekar
  • Patent number: 6627229
    Abstract: An antiviral agent of an antiviral ability against various viruses and a method of producing the same are provided. A heat treatment is applied to a calcium-containing substance represented by calcium carbonate-containing substances originating from the animal such as clamshell, eggshell, crustacean shell, bone, coral, and pearl, and calcium carbonate-containing minerals such as limestone. When a temperature of the heat treatment is not less than 650° C. and less than a melting point of the calcium component-containing substance, a sufficient time of the heat treatment is 2 to 13 hours.
    Type: Grant
    Filed: June 23, 2001
    Date of Patent: September 30, 2003
    Inventors: Kazutomo Kikuchi, Noriaki Kikuchi
  • Patent number: 6599914
    Abstract: Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: July 29, 2003
    Assignee: Schering Corporation
    Inventors: Robert P. Schleimer, John Schroeder, William Kreutner
  • Patent number: 6566396
    Abstract: Tannate compositions consisting essentially of carbetapentane tannate and chlorpheniramine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, unproductive cough and upper respiratory tract conditions are disclosed.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: May 20, 2003
    Assignee: Medpointe Healthcare Inc.
    Inventors: Ronald J. Leflein, Alexander D. D'Addio
  • Patent number: 6558618
    Abstract: A method of dispersing, in water vapor, an anti-infective therapeutic composition (10) into the air in a room (36), in order to treat or prevent transmission of upper respiratory infections, includes: adding to a reservoir of liquid water in a vaporizer (34), a therapeutic composition (10) containing one or more antibiotics (14), alcohol (16), an analgesic (18) and an expectorant (20); and vaporizing the therapeutic composition (10) into the air along with the water in the vaporizer reservoir for inhalation by persons in the room.
    Type: Grant
    Filed: April 27, 1999
    Date of Patent: May 6, 2003
    Inventor: James L Dent, Jr.
  • Patent number: 6462094
    Abstract: Compositions consisting essentially of phenylephrine tannate and guaifenesin which are effective when administered orally for the symptomatic relief of cough associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis are disclosed.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: October 8, 2002
    Assignee: Medpointe Healthcare Inc.
    Inventors: Phuong Grace Dang, Alexander D. D'Addio
  • Patent number: 6451352
    Abstract: The invention concerns the use of iso-osmotic saline solutions in particular obtained from sea water, to obtain a medicine designed for a treatment preventing and limiting the release of chemical mediators responsible for causing inflammatory phenomena in the human respiratory tracts.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: September 17, 2002
    Assignee: Laboratoires Goemar S.A.
    Inventors: Jean-Claude Yvin, Olivier Tabary, Jacky Jacquot, Edith Puchelle
  • Patent number: 6384038
    Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: May 7, 2002
    Assignee: Sepracor Inc.
    Inventor: Paul D. Rubin
  • Patent number: 6365624
    Abstract: A viscous gel for delivering minor effective homeopathic amount of zinc or another metal to the nasal membrane.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: April 2, 2002
    Assignee: Gel Tech, L.L.C.
    Inventors: Robert S. Davidson, Charles Hensley, Gary S. Kehoe
  • Publication number: 20010053787
    Abstract: Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole.
    Type: Application
    Filed: April 16, 2001
    Publication date: December 20, 2001
    Applicant: Sepracor Inc.
    Inventors: Raymond L. Woosley, A. K. Gunnar Aberg
  • Patent number: 6211246
    Abstract: The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: April 3, 2001
    Assignee: McNeil-PPC, Inc.
    Inventors: Cathy Klech Gelotte, Joanna F. Hills, Charles E. Pendley, II, Manoj N. Shah
  • Patent number: 6180663
    Abstract: A therapeutic nasal inhalant for using bioflavanoids as a topical antioxidant. The therapeutic nasal inhalant includes a method for making a therapeutic nasal inhalant composition for treating nasal mucosa. The method comprises the steps of mixing together two cups of water, one teaspoon of baking soda, one teaspoon of sodium chloride, and four milligrams of vitamin C to form a mixture. Mixing a bioflavanoid with the mixture. Allowing the mixture to stand. Filtering the mixture. Allowing the mixture to stand for a second time. Filtering the mixture.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: January 30, 2001
    Inventor: Stanley Lang
  • Patent number: 6169118
    Abstract: A synergistic flavoring combination of at least two flavoring oils and lauryl alcohol for use in an orally administered formulation which contains an ionizable zinc compound having an undesirable taste, the flavoring combination is unexpectedly effective in masking the unpleasant taste or aftertaste of zinc.
    Type: Grant
    Filed: November 4, 1999
    Date of Patent: January 2, 2001
    Assignee: Block Drug Company, Inc.
    Inventor: Essat Bilali
  • Patent number: 6121290
    Abstract: Invention is a method of treating cough in a mammal, including a human, which comprises administering to such mammal an effective amount of an inhibitor of GABA uptake.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: September 19, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: William E. Bondinell, Charles J. Kotzer, David C. Underwood
  • Patent number: 6107499
    Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug.In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 22, 2000
    Assignee: Neuromedica, Inc.
    Inventor: Victor E. Shashoua
  • Patent number: 6080783
    Abstract: A viscous gel for delivering minor effective homeopathic amount of zinc or another metal to the nasal membrane.
    Type: Grant
    Filed: September 1, 1998
    Date of Patent: June 27, 2000
    Assignees: Gum Tech International, Inc., Lawrence S. Kaye, Robert S. Davidson
    Inventors: Robert S. Davidson, Gary S. Kehoe, Lawrence S. Kaye
  • Patent number: 6063383
    Abstract: Pharmaceutical suppository composites for fever and influenza and method of producing them, therefore, are disclosed herein. More particularly, the composites combine all the advantages of traditional Chinese medicine, western medicine, and physical temperature reduction to relieve symptoms of influenza. Poisonous side effects can be avoided by using the disclosed suppositories. The pharmaceutical suppository composites comprise 2,750 g to 3,250 g radix bupleuri scorzonerifolium wild, 1,750 g to 2,250 g flos lonicerae japonicae, 1,950 g to 2,450 g fructus forsythiae, 1,650 g to 2,150 g fructus arctii, 2,550 g to 3,050 g herba schizonepetae, 50 g to 550 g calculus bovis and 870 g to 1,370 g of excipients.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: May 16, 2000
    Inventors: Wu-Ching Hsu, Su-Hsien Keng
  • Patent number: 6051585
    Abstract: An oral once-per-day single dosage unit for treating the symptoms of rhinitis expertly formulated with a nasal decongestant and antihistamine. Preferably, the antihistamine is non-sedating.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: April 18, 2000
    Inventors: Robert E. Weinstein, Alan M. Weinstein
  • Patent number: 5869479
    Abstract: Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H.sub.1 receptor antagonist; together with (b) a sufficient amount of a histamine H.sub.3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or separately in the same or different dosage forms to maintain therapeutic systemic levels of both components.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: February 9, 1999
    Assignee: Schering Corporation
    Inventors: William Kreutner, John A. Hey
  • Patent number: 5837286
    Abstract: This invention provides a taste masking composition composed of clove oil and either supportive flavor components or calcium carbonate. This taste masking composition has been found to be particularly useful to mask unpalatable medicinals in formulations which are intended to be chewed, dissolve in the mouth prior to ingestion or ingested in solution.
    Type: Grant
    Filed: January 15, 1997
    Date of Patent: November 17, 1998
    Inventors: Harish B. Pandya, Thomas P. Callahan
  • Patent number: 5760085
    Abstract: The present invention relates to topical aromatic releasing compositions containing one or more volatile aromatic compounds selected from the group consisting of 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof. In further embodiments, these compositions are also useful for providing relief from nasal symptoms.
    Type: Grant
    Filed: September 12, 1996
    Date of Patent: June 2, 1998
    Assignee: The Procter & Gamble Company
    Inventors: William Fletcher Beck, Sekhar Mitra
  • Patent number: 5730997
    Abstract: A substantially tasteless liquid phramaceutical delivery system containing an active material and a high osmolarity aqueous system comprising (i) water; (ii) about 20% to about 45% by weight sugar derivative; (iii) about 10% to about 15% by weight hydrogenated maltose syrup; and (iv) about 0% to about 35% by weight polyhydroxy alcohol.
    Type: Grant
    Filed: September 11, 1996
    Date of Patent: March 24, 1998
    Assignee: KV Pharmaceutical Company
    Inventors: Keith S. Lienhop, Robert C. Cuca, Thomas Charles Riley, Jr., R. Saul Levinson
  • Patent number: 5725865
    Abstract: Coolant compositions, flavorant compositions and ingestible and topical compositions containing at least one coolant compound selected from monomenthyl succinate, alkali metal salts of monomenthyl succinate, alkaline earth metal salts of monomenthyl succinate and mixtures thereof. These compositions are found to provide a pleasant, long-lasting cooling effect without bitterness and the cooling effect manifests itself differently than the cooling effect of other known coolants. As a result, a complementary or synergistic effect can by obtained by combination with other coolants. Further, the succinate-based coolant compounds of the invention are found to enhance the sensation of alcohol in alcoholic beverages.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: March 10, 1998
    Assignee: V. MANE Fils S.A.
    Inventors: Jean M. Mane, Jean-Louis Ponge
  • Patent number: 5726180
    Abstract: To stabilize the active ingredients, a caffeine is incorporated into a solid pharmaceutical preparation comprising a dextromethorphan and a phenylpropanolamine. The pharmaceutical preparation may further comprise ibuprofen. The active ingredients may be further stabilized, in combination with the incorporation of the caffeine, by grouping and incorporating separately each or suitably combined plural of the active ingredients into different groups or by minimizing the amount of any reducing sugar such as lactose. The solid pharmaceutical preparation is practically valuable since decomposition of each active ingredient with the lapse of time is remarkably suppressed and the active ingredients are stabilized for a longer period of time.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: March 10, 1998
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Masahiko Kurihara, Shunichi Itoh, Kou Moriyama, Mitsutaka Isobe, Kenichiro Kiyoshima
  • Patent number: 5622992
    Abstract: The present invention relates to topical aromatic releasing compositions containing one or more volatile aromatic compounds selected from the group consisting of 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof. In further embodiments, these compositions are also useful for providing relief from nasal symptoms.
    Type: Grant
    Filed: March 7, 1996
    Date of Patent: April 22, 1997
    Assignee: The Procter & Gamble Company
    Inventor: William F. Beck